Merus’ (MRUS) Buy Rating Reiterated at Guggenheim

Guggenheim reissued their buy rating on shares of Merus (NASDAQ:MRUS) in a report published on Wednesday morning,Benzinga reports.

Other equities analysts have also recently issued research reports about the stock. Needham & Company LLC restated a “buy” rating and issued a $85.00 price objective on shares of Merus in a research note on Monday, December 9th. Wells Fargo & Company began coverage on shares of Merus in a research report on Friday, February 7th. They issued an “overweight” rating and a $91.00 price target for the company. HC Wainwright reaffirmed a “buy” rating and set a $85.00 price objective on shares of Merus in a report on Monday, December 2nd. UBS Group initiated coverage on Merus in a report on Thursday, October 24th. They issued a “buy” rating and a $72.00 target price for the company. Finally, Citigroup boosted their price target on Merus from $89.00 to $97.00 and gave the company a “buy” rating in a research note on Monday, December 9th. One equities research analyst has rated the stock with a sell rating, fourteen have given a buy rating and two have given a strong buy rating to the stock. According to data from MarketBeat, Merus currently has a consensus rating of “Buy” and an average target price of $85.92.

Merus Trading Down 0.2 %

MRUS opened at $40.20 on Wednesday. The stock’s 50 day simple moving average is $41.55 and its 200-day simple moving average is $47.22. The stock has a market cap of $2.75 billion, a PE ratio of -10.18 and a beta of 1.11. Merus has a 1 year low of $37.77 and a 1 year high of $61.61.

Hedge Funds Weigh In On Merus

A number of institutional investors have recently modified their holdings of the stock. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC grew its stake in shares of Merus by 17.0% during the third quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 84,200 shares of the biotechnology company’s stock valued at $4,207,000 after purchasing an additional 12,212 shares during the last quarter. GSA Capital Partners LLP bought a new stake in Merus during the 3rd quarter worth about $675,000. State of New Jersey Common Pension Fund D acquired a new position in Merus during the 3rd quarter valued at about $1,870,000. US Bancorp DE bought a new position in shares of Merus in the 3rd quarter valued at about $103,000. Finally, HighTower Advisors LLC acquired a new stake in shares of Merus during the 3rd quarter worth approximately $358,000. 96.14% of the stock is owned by institutional investors.

Merus Company Profile

Merus N.V., a clinical-stage immuno-oncology company, engages in the development of antibody therapeutics in the Netherlands. Its bispecific antibody candidate pipeline includes Zenocutuzumab (MCLA-128), which is in a phase 2 clinical trials for the treatment of patients with metastatic breast cancer and castration-resistant prostate cancer, as well as in Phase 1/2 clinical trials for the treatment of solid tumors that harbor Neuregulin 1.